FUNDING • • 4 min read

Isomorphic Labs says the $5 billion Series C was co-led by Greenoaks and Sequoia, and states no valuation

By Ultrathink
Thumbnail for: Isomorphic Labs Raises a $5B Series C Co-Led by Greenoaks and Sequoia

Isomorphic Labs said on November 17 that it raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital. The company announcement and the PR Newswire release name the same amount, the same day, and the same co-leads. Neither states a valuation.

The numbers

  • $5 billion Series C. The company page and the wire release both print that figure.
  • Greenoaks and Sequoia Capital co-led. The wire subhead calls the round oversubscribed. The company page does not use that word.
  • Andreessen Horowitz, written as a16z, and "several other new investors" participated, along with "continued significant investment from Alphabet." Neither writeup splits the $5 billion by investor.
  • Both writeups say every existing investor participated. They name Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
  • $2.1 billion Series B on May 12, 2026, led by Thrive Capital, on the company's Series B page. That page also names Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. The Series C release does not restate the $2.1 billion or a combined total.

What the company says the round is for

The wire release says Isomorphic will keep building IsoDDE, its drug design engine, and extend it into new biology. It says the company is assembling a partner set for disease biology, building infrastructure for AI-led bioengineering, and building translational and clinical development infrastructure as candidates move toward trials.

The release says internal programs in oncology and immunology, and partnered programs, are producing positive preclinical results, and that this "sets the stage for clinical entry." It names no drug candidate, no trial, and no start date. Sir Demis Hassabis, founder and chief executive, says in the release that the round is for driving the first therapeutic programs toward clinical trials. Max Jaderberg is named as president. Neil Mehta is named as founder and managing partner of Greenoaks. Konstantine Buhler is named as a partner at Sequoia Capital.

The company says it was founded in 2021, is based in London, and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.

What is not disclosed

The Series C materials do not state a valuation, whether any valuation is pre-money or post-money, or how much Alphabet, Andreessen Horowitz, or any existing investor put in. They do not name the "several other new investors." They do not give revenue, headcount, or a date for a first clinical trial.

Quick answers

What happened with Isomorphic Labs?
Isomorphic Labs said on November 17 that it raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital. The company announcement and the PR Newswire release name the same amount, the same day, and the same co-leads. Neither states a valuation.
What are the key numbers?
$5 billion Series C. The company page and the wire release both print that figure. Greenoaks and Sequoia Capital co-led. The wire subhead calls the round oversubscribed. The company page does not use that word.

This article was ultrathought.

Pass it on

The story stays open.

The story stays open. Share it once, or start the free brief, to open the sample format.

Sample of the morning brief

Not a live send. The real brief arrives only after you confirm your email.

The example stays hidden until you share or start the brief.

Founding reader means 3 people confirm the brief from your link. The count lives on the subscriber record. This page does not show a live tally.

Related stories

More on Sequoia CapitalMore AI Funding